Rankings
▼
Calendar
TARS Q1 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$78M
+183.7% YoY
Gross Profit
$73M
93.3% margin
Operating Income
-$26M
-33.5% margin
Net Income
-$25M
-32.1% margin
EPS (Diluted)
$-0.64
QoQ Revenue Growth
+18.0%
Cash Flow
Operating Cash Flow
-$21M
Free Cash Flow
-$21M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$501M
Total Liabilities
$158M
Stockholders' Equity
$342M
Cash & Equivalents
$176M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$78M
$28M
+183.7%
Gross Profit
$73M
$26M
+181.7%
Operating Income
-$26M
-$38M
+30.3%
Net Income
-$25M
-$36M
+29.7%
Revenue Segments
Product
$78M
100%
← FY 2025
All Quarters
Q2 2025 →